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Abstract
Particulate ligands including cholesterol crystals and amyloid fibrils induce NLRP3-dependent
production of interleukin-1β (IL-1β) in atherosclerosis, Alzheimer's disease and diabetes. Soluble
endogenous ligands including oxidized-LDL, amyloid-β and amylin peptides accumulate in these
diseases. Here we identify a CD36-mediated endocytic pathway that coordinates the intracellular
conversion of these soluble ligands to crystals or fibrils, resulting in lysosomal disruption and
NLRP3-inflammasome activation. Consequently, macrophages lacking CD36 failed to elicit IL-1β
production in response to these ligands and targeting CD36 in atherosclerotic mice reduced serum
IL-1β and plaque cholesterol crystal accumulation. Collectively, these findings highlight the
importance of CD36 in the accrual and nucleation of NLRP3 ligands from within the macrophage
and position CD36 as a central regulator of inflammasome activation in sterile inflammation.
Interleukin-1β (IL-1β) has been linked to the pathogenesis of several sterile inflammatory
diseases including atherosclerosis, type 2 diabetes (T2D) and Alzheimer's disease (AD). In
each of these conditions, the accumulation of particulate materials at sites of inflammation -
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tcholesterol crystals in sub-endothelial spaces of atherosclerotic plaques1, fibrillar amyloid-β
(fAβ) in senile AD plaques2, or amyloid-containing amylin/islet amyloid polypeptide
(IAPP) on pancreatic β-cells in T2D3 – is a hallmark of disease. Recent studies have
identified these particulate endogenous ligands as activators of inflammasomes formed by
the cytoplasmic sensor NLRP3 (refs. 4, 5, 6, 7). The NLRP3-inflammasome complex
regulates activation of caspase-1, which catalyzes the cleavage of pro-IL-1β and pro-IL-18
(ref. 8), and promotes the secretion of these now biologically active cytokines as well as
IL-1α9. However, the mechanisms by which such structurally distinct molecules activate the
NLRP3 inflammasome remain elusive.
Full activation of the NLRP3 inflammasome in macrophages requires two steps: “priming”
(signal 1) and activation of inflammasome complex assembly (signal 2). Priming of
macrophages increases expression of both pro-IL-1β and NLRP3 (refs. 10, 11, 12), and can
be achieved in vitro through ligation of the Toll-like receptors (TLRs). Thus, experimental
studies typically use bacterial products to prime the NLRP3 inflammasome, as the nature of
the immunostimulatory priming signals found in atherosclerosis, AD and T2D are not well
described. Signal 2 appears to be triggered by perturbation of cytoplasmic homeostasis due
to ‘lysosomal destabilization’13. This process, triggered by certain aggregated and insoluble
materials, is characterized by the cytosolic release of lysosomal contents13 (eg. cathepsins)
and/or reactive oxygen species (ROS)14, which results in NLRP3 inflammasome assembly
and caspase-1 activation. Whether signal 1 and signal 2 are unrelated in vivo or whether
common molecular events underlie these apparently distinct processes remains undefined.
The mechanisms controlling the generation of NLRP3-activators in atherosclerosis, T2D and
AD are not well understood. For example, the deposition of cholesterol-rich lipoproteins in
the vessel wall is a key pathogenic step in atherosclerosis15, yet the origin of cholesterol
crystals which accumulate in plaques1 is poorly understood. Recent studies using combined
confocal-reflection microscopy revealed that crystals are present in early plaques, both in
extracellular spaces and within macrophages4, 16. In the AD brain and diabetic pancreas,
amyloid plaques arise from the aggregation of pre-fibrillar amyloidogenic peptides such as
the Aβ(1-42) peptide17, 18, 19 or IAPP20, 21, 22, which oligomerize and give rise to higher
order structures, including fibrils. Extracellular deposits of IAPP-amyloid in the pancreas of
T2D diabetic subjects are associated with loss of insulin-producing β-cells, and amyloid is
also detected within pancreatic macrophages which secrete IL-1β23, 24. Similarly, fAβ
peptides accumulate in extracellular plaques in the AD brain, and increasing evidence
indicates that soluble forms of Aβ are also damaging25, 26. The current paradigm suggests
that the immunostimulatory aggregates of these NLRP3 agonists form in the extracellular
space, and that their engulfment by macrophages triggers a process of dysfunctional
phagocytosis or lysosomal damage that activates the NLRP3-inflammasome and the release
of IL-1 family cytokines.
CD36 is an archetypal pattern recognition receptor that binds polyanionic ligands of both
pathogen and self-origin27, and is implicated in the pathogenesis of atherosclerosis and AD
through its recognition of modified endogenous ligands, including oxidized LDL
(oxLDL)28, fAβ29, and soluble Aβ (sAβ)30. CD36 cooperates with a TLR heterodimer of
TLR4-TLR6 to recognize oxLDL and fAβ, and induce the inflammatory response to these
endogenous ligands31. Mice lacking CD36 (Cd36–/–) mice are protected from the toxic
effects of fAβ32, atherosclerosis33, 34, insulin resistance and obesity35, 36, 37. These
observations prompted us to investigate the role of CD36 in inflammasome priming and
activation in atherosclerosis, T2D and AD. We show herein that in response to oxLDL,
CD36 initiated both signal 1 and signal 2 for complete activation of the NLRP3
inflammasome: CD36 cooperated with TLR4-TLR6 to prime the NLRP3 inflammasome,
and its unabated uptake of oxLDL, characteristic of scavenger receptors, resulted in the
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tformation of intracellular cholesterol crystals that caused lysosomal destabilization and
NLRP3 activation. We extended this example of NLRP3 activation by particulate ligands
formed from within the cell by showing that CD36 also regulated uptake of pre-fibrillar
soluble Aβ and IAPP peptides that were transformed in the lysosome to thioflavin-reactive
amyloid that triggered NLRP3. Collectively, our results suggest a new model of lysosomal-
mediated NLRP3 activation that occurs from within after de novo aggregation and
transformation of the soluble ligands into their pathogenic form. Furthermore, these studies
identify CD36 ligation as the common molecular event that links sterile ligand recognition
with NLRP3 inflammasome priming and activation in atherosclerosis, AD and T2D.
RESULTS
CD36 uptake of oxLDL generates NLRP3-activating crystals
Oxidized LDL is a key inflammatory component of atherosclerotic plaques that contains
oxidation-specific epitopes that share molecular identity with phosphorylcholine moieties
present on Streptococcus pneumoniae38. Recognition of this “danger associated molecular
pattern” (DAMP) by CD36 leads to oxLDL uptake by recruited monocytes and the
formation of cholesterol-laden macrophage foams cells which establish the atherosclerotic
lesion. Notably, oxLDL, but not unmodified LDL, induced the release of IL-1β from
lipopolysaccharide (LPS)-primed wild-type, but not Cd36–/– macrophages (Fig. 1a, left
panel). CD36 deficiency did not affect induction of IL-1β by other NLRP3 activators
including cholesterol crystals generated in vitro or ATP, or the AIM2-inflammasome
activator poly(dA:dT) (Fig. 1a, right panel). To understand how CD36-mediated uptake of
oxLDL activates the NLRP3-inflammasome, we used combined confocal-reflection
microscopy to monitor for crystalline material in macrophages. We observed a dose- and
time-dependent increase in the appearance of crystals within macrophages treated with
oxLDL, but not native LDL (Fig. 1b, Supplementary Fig. 1), and this was markedly
reduced in similarly treated Cd36–/– macrophages (Fig. 1b, Supplementary Fig. 1a).
Acetylated and minimally oxidized LDL, which bind SR-A and CD14 (but not CD36), also
induced intracellular crystal formation, albeit to a lesser extent than oxLDL
(Supplementary Fig. 1b). Treatment with methyl-β-cyclodextrin to deplete cells of
cholesterol reversed the appearance of reflective material in oxLDL-treated macrophages
confirming that this crystalline material was cholesterol (Fig. 1c). Although CD36 can act as
a TLR4-TLR6 co-receptor, oxLDL-induced crystal formation was unimpeded in Tlr4–/– and
Tlr6–/– macrophages, and oxLDL-induced IL-1β secretion from LPS-primed Tlr6–/–
macrophages was similar to wild-type macrophages (Supplementary Fig. 2a-b). However,
blocking CD36-mediated oxLDL endocytosis using cytochalasin-D inhibited both the
formation of intracellular crystals and IL-1β secretion in LPS-primed macrophages (Fig. 1d-
e), whilst induction of IL-1β by ATP was unaffected (Fig. 1e). Notably, despite similar
accumulation of crystals in oxLDL-treated wild-type and Nlrp3–/– macrophages (Fig. 1f),
secretion of IL-1β was abrogated in Nlrp3–/– macrophages confirming the dependence of
this response on the NLRP3 inflammasome (Fig. 1g). IL-1β was similarly reduced in
Nlrp3–/– macrophages treated with other NLRP3-activators, including synthetic cholesterol
crystals and ATP. Finally, oxLDL-induced IL-1β was dependent on caspase-1 as this
response was reduced in LPS-primed macrophages treated with both a broad (ZVAD-fmk)
or specific (YVAD-fmk) caspase-1 inhibitor peptide, which also inhibited IL-1β secretion
induced by synthetic cholesterol crystals, ATP and AIM2 (Fig. 1h). These data establish
CD36-regulated cholesterol crystal formation as a key driver of inflammasome activation
upstream of NLRP3.
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tLysosomes control crystal formation and NLRP3 activation
Unlike the LDL receptor, CD36 is downregulated by its ligands, leading to an unabated
uptake of oxLDL and its cholesterol cargo39. To examine the subcellular localization and
fate of oxLDL-induced crystals we used lysosomal tracers combined with confocal-
reflection fluorescence microscopy. Upon treatment of wild-type macrophages with oxLDL,
crystals appeared in acidic lysosomal compartments which stain with the lysomotropic-dye
Lysotracker within 8 hours (Fig. 2a). Labeling of lysosomes by incubating macrophages
with fluorescent dextran revealed that crystal-containing lysosomes began to destabilize
over 24 hours, as seen by the translocation of dextran into the cytosol (Fig. 2b). Similarly
treated Cd36–/– macrophages displayed a punctate perinuclear staining pattern characteristic
of intact lysososomes, consistent with oxLDL-induced crystals being the source of the
lysosomal damage (Fig. 2a,b). By contrast, treatment with pre-formed cholesterol crystals
induced the release of lysosomal dextran to a similar extent in wild-type and Cd36–/–
macrophages (Fig. 2b). Unmodified LDL did not disrupt macrophage lysosomal integrity
(Fig. 2b). We confirmed these findings using a fluorescent Lysotracker flow-cytometry
based assay in which lysosomal destabilization was quantified by the increase in
Lysotracker-negative cells. Consistent with the fluorescence microscopy findings, synthetic
crystalline cholesterol, but not unmodified LDL, increased the percentage of Lysotracker-
negative cells in both wild-type and Cd36–/– macrophages. By contrast, oxLDL increased
the Lysotracker-negative cell population in wild-type but not Cd36–/– macrophages (Fig.
2c). To further investigate the role of lysosomal function in oxLDL-triggered NLRP3
activation we inhibited macrophage lysosomal maturation using bafilomycin-A1 and
observed a marked reduction in IL-1β secretion by macrophages treated with oxLDL or
synthetic crystalline cholesterol, but not ATP or poly(dA:dT) (Fig. 2d). IL-1β inhibition was
similarly observed in macrophages treated with a broad inhibitor of the serine/protease
family of cathepsins, FA-fmK (Supplementary Fig. 2c), implicating the release of these
lysosomal enzymes in NLRP3 activation by oxLDL. Bafilomycin-A1 also blocked the
formation of cholesterol crystals by oxLDL (Fig. 2e), implicating lysosomal activity not just
in transmission of the signal to NLRP3, but also in regulating lysosomal cholesterol
crystallization. Lysosomal acidification is a key step that is blocked by bafilomycin-A1 and
is required for the hydrolysis of cholesterol esters in oxLDL by lysosomal acid lipase (LAL)
to free cholesterol, which is more readily crystallized. To test whether this catabolic event
was required for cholesterol crystallization and NLRP3 activation, we treated macrophages
with Lalistat, a specific inhibitor of LAL40. Lalistat abrogated cholesterol crystal formation
within oxLDL-treated macrophages (Fig. 2f), as well as mature IL-1β secretion (Fig. 2g),
but did not affect IL-1β secretion induced by in vitro formed cholesterol crystals. Together,
these data support the existence of a model of NLRP3-activation distinct from that of
“frustrated phagocytosis” of extracellular particulate materials, in which the unabated uptake
of oxLDL by CD36 causes the nucleation and accrual NLRP3-activating crystals within the
macrophage.
CD36 cooperates with TLR4-TLR6 to prime the inflammasome
The dual requirement for priming and activating signals for full NLRP3 activation functions
as a safeguard against the accidental or uncontrolled release of IL-1β. During the course of
our studies, we noted that oxLDL had the unusual ability to induce mature IL-1β from
unprimed macrophages, a response dependent on CD36 (Fig. 3a). As Signal 1 often
proceeds through TLRs, we investigated whether CD36 cooperative signaling with TLR4-
TLR6 provides the oxLDL priming signal. Treatment of macrophages with oxLDL alone
induced modest amounts of IL-1β which were not enhanced in the presence of the NLRP3-
activator ATP (Fig. 3a), confirming that oxLDL can provide both signal 1 and 2 for NLRP3
activation. Notably, IL-1β production was impaired in Cd36–/–, Tlr4–/– and Tlr6–/–
macrophages, indicating that this heterotrimeric signaling complex was required for NLRP3
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tpriming by oxLDL. Similar results were obtained when macrophages were primed with
oxLDL, but cholesterol crystals were used as the NLRP3 activator (Supplementary Fig.
2d). Because of the modest IL-1β amounts detected when oxLDL was used as a priming
agent, we employed macrophage-based fluorescent ASC (ASC-CFP) assay to further assess
the role of oxLDL in priming NLRP3 (ref. 11). ASC-CFP is polydispersed throughout the
cytoplasm in unstimulated macrophages, however supramolecular assembly of ASC occurs
upon signal 1 and 2, as was seen in cells primed with LPS and subsequently treated with
ATP (Fig. 3b, bottom left). Treatment with oxLDL alone induced the formation of ASC-
complexes consistent with the notion that oxLDL not only primed, but also activated
NLRP3. Treatment with ATP following oxLDL priming also induced the formation of
speck-like complexes, albeit to a lower frequency than in LPS-primed cells (Fig. 3b, c).
CD36 primes the NLRP3 inflammasome in vivo
To explore the role of CD36, TLR4 and TLR6 in transducing the oxLDL priming signal, we
measured the requirement of this signaling complex in the transcriptional induction of
inflammasome substrates and NLRP3 itself. OxLDL, but not LDL, induced Il1b and Il1a
mRNA in wild-type macrophages, whereas Il18 mRNA was unchanged consistent with its
high basal expression in macrophages (Fig. 3d, Supplementary Fig. 3). Furthermore,
oxLDL-induced macrophage Nlrp3 mRNA, a critical checkpoint in NLRP3 priming, but not
Nlrc4, an NLR involved in bacterial recognition. Notably, induction of Il1a, Il1b and Nlrp3
mRNA was not observed in Cd36–/–, Tlr4–/– and Tlr6–/– macrophages treated with oxLDL
(Fig. 3d). Triggering of CD36-TLR4-TLR6 by oxLDL induced NF-κB activation and
ROS31, two signals required for effective priming of the NLRP3-inflammasome. Consistent
with this, the induction of Il1a, Il1b and Nlrp3 mRNA by oxLDL was inhibited by the IKKβ
inhibitor BAY 11-7082 (Fig. 3e) and by the NADPH oxidase enzyme complex inhibitor DPI
(Fig. 3f). These data indicate that CD36-TLR4-TLR6, acting via NF-κB and ROS, primes
the NLRP3 inflammasome in response to oxLDL.
The endogenous NLRP3 priming signals in atherosclerosis remain unclear. We postulated
that CD36 recognition of oxidized forms of LDL that accumulate during
hypercholesterolemia can prime macrophages in vivo. To test this, we used an in vivo model
of foam cell formation by isolating peritoneal macrophages from atherogenic Apoe–/– or
Cd36–/–Apoe–/– mice fed a western diet for 12 weeks. Macrophages isolated from western
diet-fed Apoe–/– mice exhibit increased abundance of Il1a, Il1b and Nlrp3 mRNA compared
to macrophages from normolipidemic wild-type mice (Fig. 3g), indicating that these cells
were ‘in vivo primed’ for NLRP3 activity. This increase in NLRP3 priming signals was
specific, as no differences in Il18 or Nlrc4 mRNA were detected. By contrast, macrophages
from western diet-fed Cd36–/–Apoe–/– mice exhibited comparable Il1a, Il1b and Nlrp3
mRNA abundance to chow-fed mice. Furthermore, ex vivo treatment of macrophages from
western diet-fed Apoe–/– mice with the NLRP3-activator ATP (signal 2) induced IL-1β
secretion, whereas no increase in IL-1β secretion was detected in macrophages from
similarly treated Cd36–/–Apoe–/– mice (Fig. 3h). Moreover, secretion of IL-1α, a function
dependent on the inflammasome, was similarly upregulated in macrophages from western
diet-fed Apoe–/– but not Cd36–/–Apoe–/– mice treated with ATP (Fig. 3i). These data
demonstrate the requirement for CD36 in NLRP3 priming of macrophages by atherogenic
stimuli in vivo.
Targeting CD36 reduces inflammasome activation in vivo
To further investigate the role of CD36 and its signaling partners TLR4-TLR6 in
inflammasome priming and activation in vivo, we generated Apoe–/– mice deficient in
CD36, TLR4 or TLR6 and fed them a western diet for 12 weeks. Despite similar
concentrations of total cholesterol in all groups (Supplementary Table 1), aortic plaque
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tformation was significantly reduced in Cd36–/–Apoe–/–, Tlr4–/– Apoe–/– and Tlr6–/–Apoe–/–
mice compared to Apoe–/– controls (Fig. 4a, Supplementary Fig. 4). These double knock-
out mice also exhibited reduced concentrations of serum IL1β, IL1α and IL18 (Fig. 4b), as
well as Il1a, Il1b and Nlrp3 mRNA in the aorta, indicative of reduced inflammasome
activity (Fig. 4c). Furthermore, measurement of cholesterol crystal accumulation in plaques
using confocal reflection microscopy revealed a specific reduction in crystal burden in
Cd36–/–Apoe–/– mice (Fig 4d-e) supporting the hypothesis that CD36 regulates
inflammasome activity during atherogenesis by modifying both signal 1 and signal 2. We
also observed a decrease in plaque IL-1β and active caspase-1 fluorescent staining in
Cd36–/–Apoe–/–, Tlr4–/–Apoe–/– and Tlr6–/–Apoe–/– mice compared to Apoe–/– controls (Fig
4f). Nevertheless, there was a greater reduction of caspase-1 and IL-1β in Cd36–/–Apoe–/–
compared with Tlr4–/–Apoe–/– or Tlr6–/–Apoe–/– plaques, consistent with a critical role for
CD36 in both priming and activating the NLRP3 inflammasome. We next determined
whether therapeutic targeting of CD36 using an anti-sense oligonucleotide (ASO), which
potently inhibits CD36 expression in macrophages in vitro and in vivo (Supplementary Fig.
5), could prevent inflammasome activation in western diet-fed Apoe–/– mice. Notably,
serum IL-1β increased in Apoe–/– mice receiving weekly injections of control-ASO, but not
CD36-ASO, over 4 weeks (Fig. 4g).
CD36 regulates amyloid formation and NLRP3 activation
Like atherosclerosis, AD is characterized by a protracted inflammatory response driven by
cells of the monocyte lineage. fAβ activates the NLRP3 inflammasome and IL-1β secretion
in LPS-primed macrophages and microglia5, and a recent study demonstrated that NLRP3
activation contributes to AD41. We recently showed that CD36 binds to soluble (pre-
fibrillar) Aβ30 prompting us to investigate whether CD36 uptake of this soluble ligand could
also promote the intracellular generation of an NLRP3-activator. We treated macrophages
with sAβ, which was confirmed to be non-fibrillar (Supplementary Fig. 6a), and stained
with thioflavin-S, a dye that becomes fluorescent upon binding amyloid oligomers and
fibrils. Confocal microscopy revealed a time-dependent increase in the appearance of
intracellular thioflavin-S fluorescence in wild-type but not Cd36–/– macrophages treated
with sAβ (Fig. 5a). Macrophages incubated with the non-amyloidogenic reverse peptide
(revAβ) revealed no evidence of thioflavin-S-reactivity for up to 24 h, whereas thioflavin-S-
reactive amyloid was apparent in wild-type macrophages as early as 3h after addition of sAβ
and localized to lysosomes (Fig. 5a,b). No extracellular or cell-associated fibrils were
observed by confocal microscopy (Fig. 5a, b), and sAβ incubated at 37 °C in cell culture
medium for up to 24 hours showed no evidence of thioflavin-T reactivity (Supplementary
Fig. 6b). Over that time frame (3-24h), sAβ induced the progressive release of IL-1β when
incubated with LPS-primed wild-type, but not Nlrp3–/– or Ice–/– (caspase-1 knock-out)
macrophages, indicating that uptake of this soluble ligand resulted in NLRP3-activation
(Fig. 5c, Supplementary Fig. 6b, lower panel). Of note, sAβ was as effective an NLRP3-
activator as fAβ, and pretreating macrophages with Congo Red to interfere with β-sheet
formation blocked IL-1β secretion (Fig. 5d). Finally, secretion of IL-1β by sAβ was
abrogated in Cd36–/– macrophages, indicating the critical role of this receptor-mediated
uptake pathway in the generation of intracellular NLRP3-activating amyloid (Fig. 5e).
Recent studies identified activation of the NLRP3-inflammasome by another amyloidogenic
peptide, IAPP, as a mechanism for enhanced IL-1β in T2D6. Interestingly, IAPP peptides
delivered to macrophages in a soluble form were preferential activators of NLRP3 (ref. 6).
We postulated that CD36-mediated uptake of IAPP may promote intracellular amyloid
formation and NLRP3-activation, as observed with sAβ. Binding of a fluorescently-labeled
human IAPP peptide (FAM-IAPP) or HiLyte-tagged sAβ was increased in cells stably
overexpressing CD36 (CHO-CD36) compared to control cells (CHO-eV) (Fig. 6a).
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tFurthermore, wild-type but not Cd36–/– macrophages incubated with soluble huIAPP
showed a time-dependent increase in intracellular thioflavin-S fluorescence (Fig. 6b). No
such increase in thioflavin-S staining was observed in macrophages treated for up to 24
hours with rat IAPP, which is non-amyloidogenic due to species-specific amino acid
differences (Fig. 6b). The intracellular accumulation of thioflavin-S-reactive amyloid altered
lysosomal stability, as wild-type macrophages treated with fluorescent dextran and
incubated with huIAPP or sAβ for 24 h showed a loss of lysosomal integrity, evidenced by
the leakage of dextran into the cytoplasm (Fig. 6c). Soluble IAPP induced the progressive
release of IL-1β, from as early as 3h, when incubated with LPS-primed wild-type but not
Nlrp3–/– or Ice–/– macrophages. (Fig. 6d, Supplementary Fig. 6c). By contrast, soluble
IAPP incubated at 37°C in cell culture medium alone showed no evidence of thioflavin-T
reactivity for up to 12 hours. Notably, the lysosomal damage induced by these
amyloidogenic peptides, and subsequent IL-1β secretion, were abrogated in Cd36–/–
macrophages (Fig. 6c, e). Furthermore, pre-treating macrophages with Congo Red blocked
the accumulation of thioflavin-reactive IAPP and IL-1β secretion (Fig. 6f), indicating that
the intracellular transformation of soluble IAPP resulted in NLRP3 activation. Moreover and
consistent with what we observed with oxLDL-induced cholesterol crystals, phagolysosomal
activity was required for NLRP3 activation by huIAPP and sAβ as pre-treatment with
cytochalasin-D to block endocytosis, bafilomycin-A1 to block lysosomal acidification or
FA-fmk to inhibit the serine/protease family of cathepsins, blunted IL-1β production
(Supplementary Fig. 6d-e). These data support the existence of a common pathway
through which CD36-mediated uptake of the soluble precursors of NLRP3 ligands facilitates
the intracellular generation of pathogenic NLRP3 activators.
DISCUSSION
Our work here identifies CD36 as a master regulator of inflammasome activation in
atherosclerosis, AD and T2D that facilitates the accrual and intralysosomal conversion of
soluble endogenous ligands (oxLDL, sAβ and IAPP) to insoluble crystals or amyloid
oligomers/fibrils and consequently, NLRP3 activation leading to IL-1β secretion. Lysosomal
dysfunction plays a critical role in both the generation of crystalline and amyloid ligands,
and the transmission of the damaging effects of these ligands sensed by NLRP3. Our results
suggest a new model of NLRP3 activation by particulate ligands formed from within the
macrophage, and place CD36 upstream of a common mechanism of NLRP3-dependent
IL-1β secretion in several sterile inflammatory diseases.
In each of the diseases focused on in this study, the accumulation of particulate materials at
sites of inflammation is a pathological hallmark. Unlike previously proposed models of
NLRP3 activation in these diseases in which “frustrated phagocytosis” of extracellular
particulate materials triggers the inflammasome4, 5, our findings suggest that the earliest
activation of NLRP3 by cholesterol crystals or Aβ/IAPP fibrils results from recognition and
endocytosis of the soluble precursors of particulate ligands (eg. oxLDL, sAβ, sIAPP) by
CD36 and the subsequent intracellular nucleation of insoluble NLRP3-activators. Our data
fit with previous observations of intracellular amyloid fibril formation in
vitro23, 24, 25, 26, 42, 43, and an increasing literature that suggests that sAβ and sIAPP are the
damaging species in AD and T2D, respectively. In addition to fibrillar forms of amyloid,
macrophages incubated with sAβ and sIAPP may also contain higher order oligomeric
forms of these peptides in the lysosome that may activate NLRP3. Whilst these studies do
not exclude the possibility that extracellular crystals or amyloid fibrils exist which also
activate the NLRP3 inflammasome through the ‘frustrated phagocytosis’ process, here we
expand upon this paradigm by suggesting that such ligands may be secondary triggers of
NLRP3 that arise later in disease due to their active export from macrophages or the release
of crystals/fibrils from dying cells. Macrophage cell death may itself be triggered by
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tinflammasome activation through the process known as pyroptosis44 which is linked to the
release of pro-atherogenic IL1α45, 46, 47, or as a result of lysosomal dysfunction due to the
prolonged accumulation of insoluble crystals or fibrils.
In the case of atherosclerosis, CD36 plays a dual role in initiating both priming (signal 1)
and activation (signal 2) of the NLRP3 inflammasome. Although oxLDL has been known to
trigger IL-1β production in foam cells48, 49, 50, many of these studies were carried out before
identification of the NLRP3-inflammasome. Our work provides the molecular mechanism
for how oxLDL induces macrophage secretion of IL-1β by showing that CD36 binding of
this ligand controls its engagement of the two necessary pathways for full inflammasome
activation: Signal 1 via the TLRs and Signal 2 via the NLRs. Whilst previous studies of
inflammasome activity in host defense and inflammatory disease have suggested that signal
1 and signal 2 are derived from separate DAMPS engaging distinct signaling pathways, our
data suggests that a single DAMP (oxLDL) provides both signals in atherosclerosis by
engaging CD36. Whilst the amounts of priming signals induced by oxLDL via CD36-TLR4-
TLR6 are modest compared to a bacterial stimuli it is consistent with atherosclerosis arising
from low-grade inflammation over a protracted period of time, and our in vivo data confirm
the importance of this receptor complex in both NLRP3 priming and atherosclerotic plaque
formation. Notably, CD36 deficiency in Apoe–/– mice also causes a striking reduction in
cholesterol crystal accumulation in plaques and serum IL-1 family cytokines (IL-1β, IL-1α,
IL-18) concentrations, arguing that the CD36-dependent pathway for intracellular crystal
generation identified in vitro is also active in vivo. The endocytosis of ligands by CD36,
which leads to the nucleation of NLRP3 activators, can therefore be thought of as ‘Signal 0’
in models of inflammasome activation by sterile inflammatory stimuli, providing the
common cellular event required for priming and activation of NLRP3 in metabolic diseases.
The incidence of atherosclerosis and T2D continues to increase and the development of new
therapeutics for metabolic disease is crucial. The appreciation of the critical role of the
NLRP3 inflammasome in both atherogenesis and T2D highlights the promise of this
pathway for therapeutic targeting. Whilst many studies have described regulators of
inflammasome activity at the level of complex assembly and caspase-1 activation51, the
identification of CD36 as a key upstream regulator of NLRP3 activation by endogenous
danger ligands in atherosclerosis, AD and T2D provides a new target for the therapeutic
intervention which does not compromise inflammasome activity required for host defense
against pathogens. To our knowledge, this is the first such upstream regulator of NLRP3
described in sterile inflammation, with CD36 fulfilling a role analogous to the P2X7
receptor for ATP-mediated activation of NLRP3 (ref. 52). CD36 targeting for amelioration
of NLRP3 activation may be particularly useful for atherosclerosis, where CD36 is essential
for inflammasome priming and activation in macrophage foam cells, as well as the
accumulation of cholesterol crystals in plaques. Supporting this, we find that targeting CD36
using antisense oligonucleotides reduces serum IL-1β concentrations in atherosclerotic
mice, suggesting that such strategies may hold promise for reducing inflammasome
activation in human disease.
METHODS
Mice & Cell Culture
Cd36–/–, Tlr4–/–, Tlr6–/–, Nlrp3–/– and Ice1–/– mice were described5, 31. C57BL/6J mice
were purchased from Jackson Laboratories. For peritoneal macrophage isolation, mice were
injected intraperitoneally with 1mL 4% thioglycollate medium solution (Gibco) and
peritoneal elicited cells isolated by washing the peritoneal cavity with 5 mL PBS 4 days
post-injection. To separate macrophages, red blood cells were lysed and resulting cells
seeded at 2×106 cell/mL in DMEM media (Gibco) containing 10% FBS. Macrophages were
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tallowed to adhere overnight and then media was changed to DMEM containing 2% FBS.
Bone-marrow derived macrophages (BMDM) were isolated by flushing the bone marrow
from femur and tibia of hind-legs from mice using DMEM containing 10% FBS
supplemented with antibiotics as above. Cells were collected, centrifuged, lysed as above
and resulting cells seeded at 1×106 cell/mL in DMEM containing 10% FBS and
supplemented with conditioned media from L929 cells (15%) as described53. Cells were
differentiated until day 5 after which they were harvested using 10 mM EDTA and plated at
1×106 cell/mL in DMEM containing 2% FBS and 7.5% L929 conditioned media.
Immortalized macrophages stably transfected with a construct overexpresssing CFP-tagged
murine ASC were described11. CHO cell lines stably transfected with plasmids
overexpressing CD36 (CHOCD36) or empty vector control (CHO-eV) were described30 and
maintained in RPMI containing 10% FBS supplemented with antibiotics.
Mice & Atherosclerosis Studies
Apoe–/– and Cd36–/–Apoe–/– mice were described34. Tlr4–/–Apoe–/– and Tlr6–/–Apoe–/–
mice were generated by inter-crossing Apoe–/– and Tlr4–/– or Tlr6–/– mice on C57/BL6J
background31. Double knock-out offspring were viable and born at a Mendelian ratio. All
mice were housed in a pathogen-free environment in autoclaved filter-top cages with
autoclaved water and kept on a 12-hour light/dark cycle. All experiments were approved by
the New York University School of Medicine Institutional Animal Care and Use Committee.
Beginning at 5-6 weeks of age, mice were fed a modified western diet (DYET#100244
containing 3 gm/kg cholesterol, Dyets Inc) for 12 weeks. At sacrifice, mice were
anesthetized with isoflurane and exsanguinated by cardiac puncture. Hearts were perfused
with PBS and the arterial system was perfusion-fixed with 10% formalin for lesion analysis
or with RNA Later Soln. (Ambion) for RNA analysis. The heart and upper section of aorta
was removed, cleaned of peripheral fat under a dissecting microscope and dissected directly
under and parallel to the aortic leaflets. The upper section was embedded in OCT medium
and snap-frozen immediately. For quantification of lesions in the aorta en face, the aorta was
dissected so that it was free of all branching vessels, incised ventrally from the aortic root to
the bifurcation of the iliac arteries and stored in PBS. Images of aortae were digitally
captured and lesion area selected with IP Lab Spectrum software. Lesion area was calculated
as a percentage of the total area of the whole aorta or defined regions of the aorta, including
the aortic arch, thoracic, abdominal, and ileal areas (descending). Hearts embedded in OCT
were sectioned through the aortic root (8 μm) and stained with hematoxylin and eosin for
lesion quantification or used for immunofluoresence analysis. Serum was isolated from
terminal bleeds at the time of sacrifice and used for determination of total cholesterol (Wako
Cholesterol E kit) or stored frozen for analysis of cytokines. For experiments with CD36
antisense oligonucleotides, mice were injected with the CD36-specific ASO (CD36) or a
non-targeting control ASO (Ctrl) provided by Isis Pharmaceuticals, at 50 mg/kg
subcutaneously in endotoxin-free PBS (10 μL/g body weight). At 5 weeks of age mice were
randomized into 2 groups (receiving Ctrl and CD36 ASO), bled for baseline measurements
and received 2 injections spaced 2 days apart. One week post initial injection, mice were fed
a western diet (DYET#100244) or 4 weeks, and continued to receive once weekly injections
of ASO. Mice were bled at termination and serum cytokines were measured by ELISA. Both
ASOs were 20-mer second generation MOE gapmers of the 5-10-5 design. Specifically, the
phosphorothioate oligonucleotides contained 2'-0-(2-methoxyethyl)-modified
ribonucleosides (2'-MOE) groups at positions 1 to 5 and 16 to 20 with 2'-deoxynucleosides
at positions 6 to 15. The sequences of both ASOs were as follows: CD36 ASO, 5'-
GAATGGATCTTTGTAACCCC-3' and Ctrl ASO, 5'-CCTTCCCTGAAGGTTCCTCC-3'.
The Ctrl ASO does not hybridize to any known target and was used to control for any ASO
class effects that could impact inflammasome activation
Sheedy et al. Page 9
Nat Immunol. Author manuscript; available in PMC 2014 February 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tReagents
Human LDL (BT-903) and acetylated LDL (BT-906) were obtained from Biomedical
Technologies, Inc. For preparation of oxidized LDL (oxLDL), LDL was diluted in PBS to
250 μg/mL and dialysed overnight in 3L PBS at 4°C. Moderately oxidized LDL was
prepared by dialysis against 5 μM CuSO4 for 6h, and terminated by the addition of EDTA
(200 nM) and butylated hydroxytlouene (500 nM). To obtain minimally modified LDL
(mmLDL) and extensively oxidized LDL (ex-oxLDL) dialysis against against 5 μM CuSO4
was terminated after 2h or 24h respectively. Cholesterol was obtained from Sigma-Aldrich
and crystallized as described7. ATP and poly(dA:dT) [poly(dA-dT)•poly(dT-dA)] was from
Sigma-Aldrich. poly(dA:dT) was delivered to the cytoplasm using transfection with
Lipofectamine 2000 (Invitrogen). Amyloid-β (Aβ) and islet amyloid polypeptide (IAPP)
peptides were obtained from California Peptides. Soluble β-amyloid (sAβ) was generated by
resuspending human Aβ1-42 peptide at 5 mg/mL in DMSO, distributed in aliquots and
frozen immediately as described30. Non-amyloidogenic control reverse peptide (revAβ) was
made soluble by similarly treating human Aβ42-1 peptide. This method of preparation does
not generate fibrillar Aβ as assessed by thioflavin-T fluorescence and electron microscopy.
Soluble human IAPP (hIAPP) was resuspended in endotoxin-free water at 1 mg/mL as
described6. Non-amyloidogenic control rat IAPP was prepared similarly. All reagents were
sterile and endotoxin-free, as confirmed by Limulus amebocyte lysate testing using
PYROGENT kit (Lonza). Ultrapure LPS (Alexis) was used at 200 ng/mL for 6 h for
priming. In some experiments, following 6 h priming, media was changed to DMEM
containing 2% FBS and cells were pretreated with the following inhibitors for 1 h before
stimulation with NLRP3 activators; cytochalasin-D, bafilomycin-A1, Congo red (all from
Sigma-Aldrich), or Lalistat (kind gift of F. Maxfield, Weill Cornell, NY). The broad
spectrum caspase inhibitor ZVAD-fmk (benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone), the caspase-1 specific inhibitor z-YVAD-fmk (benzyloxycarbonyl-
Tyr-Val-Ala-Asp-fluoromethylketone) and z-FA-fmk (benzyloxycarbonyl-Phe-Ala-
fluoromethylketone), an irreversible inhibitor of cysteine proteases that do not require a P1
Asp residue, such as cathepsin B, L, and S, were from Santa Cruz Biotechnology Inc. In
some experiments cells were pretreated with BAY 11-7082 (Calbiochem) or
diphenyliodonium chloride (DPI – Sigma-Aldrich) 1 h prior to priming.
Molecular biology
RNA was isolated from cells/tissues using TRIzol reagent (Invitrogen/now Ambion)
according to the manufacturers protocol. 1 μg RNA was reverse-transcribed to generate
cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). Gene expression was measured by
real-time quantitative RT-PCR (qRT-PCR) using SYBR Green for quantification (KAPA
SYBR FAST Universal qPCR Kit – KAPA Biosystems), on an Eppendorf realplex4
Mastercycler platform. Primers sequences are listed below and each primer pair was tested
to find optimal primer concentration prior to use, commonly between 100-200 nM. Ct values
for each gene were normalized to housekeeping genes Gapdh or Hprt and relative expression
calculated using the ΔΔCt method. Murine primer sequences used were: Gapdh; Fwd 5'-
AGGTCGGTGTGAACGGATTTG-3', Rev 5'-TGTAGACCATGTAGTTGAGGTCA-3',
Hprt; Fwd 5'-TCAGTCAACGGGGGACATAAA-3', Rev 5'-
GGGGCTGTACTGCTTAACCAG-3', Il1b; Fwd 5'-TGTGAATGCCACCTTTTGACA-3',
Rev 5'-GGTCAAAGGTTTGGAAGCAG-3', Il1a; Fwd 5'-
GCACCTTACACCTACCAGAGT-3', Rev 5'-AAACTTCTGCCTGACGAGCTT-3', Il18;
Fwd 5'-GACTCTTGCGTCAACTTCAAGG-3', Rev 5'-
CAGGCTGTCTTTTGTCAACGA-3', Nlrp3; Fwd 5'-ATTACCCGCCCGAGAAAGG-3',
Rev 5'-TCGCAGCAAAGATCCACACAG-3', Nlrc4; Fwd 5'-
TTGAAGGCGAGTCTGGCAAAG-3', Rev 5'-GGCGCTTCTCAGGTGGATG-3', and
Cd36; Fwd 5'-ATGGGCTGTGATCGGAACTG-5', Rev 5'-
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tGTCTTCCCAATAAGCATGTCTCC-3';. Silencing of CD36 in vitro was assessed by
transfection of immortalized macrophages with 10 ng ASO per well in 12 well plates using
Lipofectamine RNAiMax (Invitrogen).
Serum array and ELISA
Mouse serum was used for multiplex analysis of cytokines using Quantibody Mouse
Inflammation Array 1 (QAM-INF-1 – Raybiotech Inc.) according to the manufacturers
instructions. Serum IL-18 ELISA was performed using Mouse IL-18 ELISA Kit (MBL -
#7625). ELISA analysis of supernatants was performed using specific DuoSet ELISA kits
from R&D Systems - IL-1β (DY401) and IL-1α (DY400).
Microscopy
For analysis of speck formation using ASC-CFP transfected macrophages, cells were seeded
in 8-well Lab-Tek chamber slides (Thermo Scientific) and following the experiment fixed in
4% paraformaldehye (IC Fixation Buffer, 1x concentrate - Invitrogen), washed with PBS
and stained using Alexa Fluor 594-coupled cholera toxin subunit B (AF594-CTB -
Invitrogen) at 2 μg/mL and counterstained with 4’,6-Diamidino-2-Phenylindole (DAPI -
Sigma) at 0.5 μg/mL prior to mounting with Fluorescent Mounting Medium (Dako). Cells
were visualized using Confocal Microscopy (Zeiss 600 System). Images taken at 63X were
merged using ImageJ. For quantification of speck formation, images were taken using
epifluoresence microscopy at 20X. For analysis of crystal formation alongside lysosomal
markers live cell imaging was performed. Briefly, cells were seeded in 35 mm petri dishes
on 0.16 mm coverglasses and allowed to adhere overnight. Cells were then pre-treated with
Alexa Fluor 647-coupled Dextran (10 kDa MW - Invitrogen) at 50 μg/mL or Lysotracker
Red DND-99 at 100 nM for 1 h prior to treatment with inflammasome activators. Combined
confocal reflection microscopy was performed at various time points using a Leica SP2
AOBS confocal laser-scanning microscope as described13. For analysis of amyloid
formation cells were seeded in 8-well Lab-Tek chamber slides as above and following the
experiments fixed in 10% paraformaldehyde, washed with PBS, stained using AF594-CTB
as before, washed with PBS, permeabilized using 0.1 % Triton X-100 for 20 min followed
by staining with 0.01 % thioflavin-S. After staining cells were washed five times with 70 %
EtOH followed by 2 washes with PBS, stained with DAPI and mounted as above. Cells were
imaged using a Nikon Ti (Eclipse) inverted microscope with Ultraview Spinning Disc
(CSU-X1) confocal scanner (Perkin Elmer). Images were captured with an Orca-ERCamera
using Volocity (Perkin Elmer). Post acquisition analysis such as contrast adjustment,
deconvolution through iterative restoration and 3D reconstruction were performed using
Volocity software.
Immunofluoresence staining
Slides containing 8 sections covering the aortic root were fixed in acetone, blocked using 10
% serum (specific to species secondary antibodies were raised in) in PBS and stained with
antibodies for CD68 (rat anti-mouse IgG, Serotec) as described before or IL1β (goat anti-
mouse IgG, AF-401-A, R&D Systems) at 1 μg/mL at 4°C overnight. Slides were washed
and incubated with Alexa Fluor-coupled secondary antibodies: AF-568 goat anti-rat IgG for
CD68 stains, AF-568 rabbit anti-goat IgG for IL-1β staining, at 2 μg/mL for 2 h at 21 °C.
Sections were then incubated with fluorescent peptide-based probes for active caspase-1
(FAM-YVAD-fmk – FLICA Caspase 1 Kit #98 – ImmunoChemistry Technologies) used at
3X, 2h at 21 °C. Slides were then washed and counterstained with DAPI before mounting as
above. Aortic root plaques were visualized using epifluoresence microscopy. For
quantification of caspase-1 activity and IL-1β staining, the area positive for staining in
plaques was expressed as a percentage of total area using Image J software. For analysis of
plaque crystal content, tissue sections were fixed with 4 % paraformaldehyde to preserve
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tcrystalline material, nuclei were stained with Hoechst 33342 (Immunochemistry) and
combined confocal reflection microscopy was performed using a Leica TCS SP5 II AOBS
confocal laser-scanning microscope as described13. Plaque crystal content was quantified
using Volocity Quantitation (Perkin Elmer) and is expressed as a percentage of total plaque
area.
Flow Cytometry
For evaluation of lysosomal damage, cells were incubated with Lysotracker Red DND-99 (1
μM) for 1 h prior to stimulation with inflammasome activators. Lysosomal damage was
defined as loss of Lysotracker fluorescence, as assessed by flow cytometry. For evaluation
of binding of soluble peptides, a fluorescently tagged human IAPP peptide which contains a
fluorescent dye conjugate on the N terminus (FAM-huIAPP) or Hilyte-Fluor 488 conjugated
human Aβ1–42 (488-Aβ) were obtained from AnaSpec Inc., Freemont, CA and made soluble
as described above. Binding to CHO cells was determined following 2 h incubations using
flow cytometry to measure associated fluorescence as described54. Briefly, extracellular
fluorescence was quenched with 0.2% trypan blue shortly before analysis and binding was
calculated as the difference between total cell-associated fluorescence and intracellular
fluorescence. All flow cytometry measurements were carried out using an Accuri C6 Flow
Cytometer (BD Biosciences).
Statistical analysis
Statistical significance was assessed by a one way analysis of variance for multiple
comparisons or an unpaired, two-tailed Student's t-test for single comparison. A P value of
less than 0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. CD36-mediated uptake of oxLDL generates intracellular crystals and activates the
NLRP3 inflammasome
(a) IL-1β ELISA of supernatants from LPS-primed wild-type (WT) or CD36-deficient
(Cd36-/-) BMDM incubated for 24 h with PBS vehicle (Ctrl), oxLDL or unmodified LDL
(left panel) alongside the following inflammasome activators (right panel), cholesterol
crystals (CC, 1 mg/mL), ATP (5 μM, 1 h) and poly(dA:dT) [p(A:T), 100 ng/well, 6 h]. (b)
Confocal reflection microscopy of WT or Cd36-/- peritoneal macrophages treated for 24 h
with oxLDL as indicated. (c) Confocal reflection microscopy of peritoneal macrophages
treated with oxLDL (50 μg/mL, 24 h) and subsequently treated with methyl-β-cyclodextrin
(MβCD, 10 μM, 1 h) or vehicle (Veh). (d) Confocal reflection microscopy of oxLDL-
treated BMDM (50 μg/mL, 24 h) following pre-treatment with cytochalasin D (Cyt D (1
μM, 1 h) or vehicle control (Veh). (e) IL-1β ELISA of supernatants from LPS-primed
BMDM treated for 24 h with PBS vehicle (Ctrl), oxLDL (50 μg/mL) or cholesterol crystals
and ATP as before. (f) Confocal reflection microscopy of WT or NLRP3-deficient (Nlrp3-/-)
BMDM treated with oxLDL (50 μg/mL, 24 h). (g) IL-1β ELISA of supernatants from LPS-
primed WT or Nlrp3-/- BMDM treated as in a). (h) IL-1β ELISA of supernatants from LPS-
primed BMDM treated with the indicated inflammasome activators following 1 h pre-
treatment with ZVAD-fmk (pan-caspase inhibitor, 20 μM) or YVAD-fmk (caspase-1
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tinhibitor, 20 μM). Data in a, e, g and h are mean ± s.d. of triplicate samples within a single
experiment and are representative of three independent experiments. Images in b, c,d and f
are representative of 3 independent experiments. Scale bar = 10 μm. *P<0.05.
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tFigure 2. CD36-mediated cholesterol crystal formation and NLRP3 activation occurs via a
lysosomal pathway
(a) Combined confocal reflection microscopy of wild-type (WT) or CD36-deficient
(Cd36–/–) BMDM incubated for 8 h with oxLDL (50 μg/mL) alongside Lysotracker-Red.
(b) Combined confocal reflection microscopy of WT or Cd36–/– BMDM incubated for 24 h
with PBS vehicle (Ctrl), oxLDL (50 μg/mL), unmodified LDL (50 μg/mL) or cholesterol
crystals (CC, 1 mg/mL) alongside fluorescent Dextran-Red. (c) Flow cytometry
measurements of Lysotracker Red-fluoresence in WT or Cd36–/– BMDM treated as in (b).
(d,g) IL-β ELISA of supernatants from LPS-primed BMDM incubated the indicated
inflammasome activators following pre-treatment with 500 nM bafilomycin A1 (BafA1) (d)
or 20 nM Lalistat (g). (e,f) Confocal reflection microscopy of oxLDL-loaded BMDM (50
μg/mL, 24 h) following pre-treatment with BafA1 or Lalistat (as in d and g). Data in d and g
are mean ± s.d. of triplicate samples within a single experiment and are representative of
three independent experiments. Images in a-c, e and f are representative of three independent
experiments. Scale bar = 10 μm. *P<0.05.
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tFigure 3. CD36 regulates priming of the NLRP3 inflammasome by oxLDL through TLR4-TLR6
(a) IL-1β ELISA of supernatants from wild-type (WT), CD36-deficient (Cd36–/–), TLR4-
deficient (Tlr4–/–) or TLR6-deficient (Tlr6–/–) peritoneal macrophages primed with oxLDL,
unmodified LDL (50 μg/mL, 18 h) or PBS vehicle (Ctrl) and subsequently treated with ATP
(5 μM, 1 h). (b) Confocal microscopy of ASC-CFP expressing immortalized macrophages
treated as indicated. (c) Quantification of ASC-oligomerization (speck formation) per 20x
field for the indicated treatments. (d-f) Relative mRNA expression of the indicated gene in
oxLDL-treated WT, Cd36–/–, Tlr4–/– or Tlr6–/– peritoneal macrophages (d) or from WT
peritoneal macrophages following pre-treatment with BAY 11-7083 (BAY, an NF-κB
inhibitor, 10 μM,) (e) or diphenylene iodonium (DPI, an NAPDH oxidase inhibitor, 1 μM)
(f), measured by qRT-PCR. (g) Relative mRNA expression in in-vivo formed foam cell
macrophages from mice of the indicated genotype fed a western diet and expressed relative
to macrophages from chow-fed mice. (h-i) IL-1β (h) or IL-1α (i) production from in-vivo
formed foam cells from mice of the indicated genotype treated ex-vivo with ATP (5 μM, 1
h). Data in a, h-i are mean ± s.d. of triplicate samples within a single experiment and are
representative of three independent experiments. Data in c-f and g is mean ± s.e.m. of three
independent experiments. Images in b are representative of three independent experiments.
Scale bar =10 μm. *P<0.05.
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tFigure 4. Inflammasome activity is impaired in atherogenic mice deficient in CD36 and its
signaling partners TLR4 and TLR6
Mice of the indicated genotype (Apoe–/–, Cd36–/–Apoe–/–, Tlr4–/– Apoe–/–, Tlr6–/–Apoe–/–,
or control C57/BL6 Apoe+/+) were fed a western diet for 12 weeks, and atherosclerosis and
inflammasome activity was assessed. (a) Lesion area in the aorta en face measured as a % of
total aortic area. (b) Serum cytokine concentrations measured by Raybiotech Protein Array
(IL1β, IL1α) or ELISA (IL18). (c) qRT-PCR analysis of aortic mRNA. (d-e) Plaque crystal
content measured in serial sections throughout aortic root by combined confocal reflection
microscopy illustrated in (e) and quantified in (d). (f) Plaque caspase-1 activity measured in
serial sections throughout aortic root using FAM-YVAD-fmk FLICA probe fluorescence
(left) or anti-IL-1β immunofluorescent staining (right) (n=8 sections/mouse) and expressed
as % of total plaque area. (g) Serum IL-1β concentrations from Apoe–/– mice before (chow)
or after western diet (WD) feeding for 4 wk during which mice were treated with a non-
targeting or CD36 antisense oligonucleotide (ASO). Data is presented for n=15 mice
(Apoe–/–), n=10 mice/group (Cd36–/–Apoe–/– and Tlr4–/–Apoe–/–) and n=7 mice
(Tlr6–/–Apoe–/–) (a,d). Horizontal bars indicate the mean and symbols indicate individual
mice. All other data is mean ± s.e.m. for n=4 mice/group (b-c), n=6 mice/group (f) and n=5
mice/group (g). Scale bar = 200 μm. *P<0.05.
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tFigure 5. CD36 uptake of soluble Aβ induces intracellular NLRP3-activating amyloid formation
(a) Confocal microscopy of wild-type (WT) or CD36-deficient (Cd36–/–) BMDM incubated
with 10 μM soluble Aβ for the indicated times or control reverse peptide (reverse Aβ) for 24
h. After incubation cells were fixed and stained with Alexa-568 conjugated cholera toxin B
and thioflavin-S (Thio-S) to visualize intracellular amyloid. (b) Confocal microscopy of
BMDM incubated for 6 h with soluble Aβ (10 μM) and fluorescent Dextran as a lysosomal
marker, then fixed and stained with thioflavin-S to visualize intracellular amyloid. (c) IL-1β
ELISA of supernatants from LPS primed WT, NLRP3-deficient (Nlrp3–/–) or Caspase-1
deficient (Ice–/–) BMDM treated for 24h with DMSO-vehicle (Ctrl), soluble Aβ (sAβ, 10
μM) or fibrillar β-amyloid (fAβ, 1 μM). (d) IL-β ELISA of supernatants from LPS-primed
BMDM pre-treated with Congo red (200 μM) for 1 h and incubated for 24h with DMSO
vehicle (Ctrl) or sAβ (10 μM). (e) IL-1β ELISA of supernatants from LPS primed WT or
Cd36–/– BMDM treated for 24 h with DMSO-vehicle (Ctrl), sAβ (10 μM) or reverse peptide
(revAβ, 10 μM). Data in c-e are mean ± s.d. of triplicate samples within a single experiment
and are representative of three independent experiments. Images in a-b are representative of
three independent experiments. Scale bar = 10 μm. *P<0.05.
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tFigure 6. CD36 regulates NLRP3 activation by IAPP
(a) Binding of FAM-conjugated human IAPP, (FAM-IAPP; 5-10 μM) and HiLyte-488-
conjugated soluble Aβ (488-sAβ) to control (CHO-eV) or CD36-expressing CHO (CHO-
CD36) cells. (b) Confocal microscopy of WT or Cd36–/– BMDM incubated with 10 μM
soluble human IAPP for the indicated times or control rat IAPP for 24 h. Cells were fixed
and stained with Alexa-568 conjugated cholera toxin B and thioflavin-S (Thio-S) to
visualize intracellular amyloid. (c) Confocal microscopy of WT or Cd36–/– BMDM
incubated with human IAPP (hIAPP) or soluble Aβ (sAβ, 10 μM, 24 h) and fluorescent
Dextran-Red, then fixed and stained with thioflavin-S. Arrows indicate thioflavin-S-reactive
amyloid. (d) IL-1β ELISA of supernatants from LPS primed WT, NLRP3-deficient
(Nlrp3–/–) or Caspase-1 deficient (Ice–/–) BMDM treated for 6 h with vehicle (Ctrl) or
huIAPP (10 μM). (e) IL-1β ELISA of supernatants from LPS primed WT or Cd36–/–
BMDM treated for 6h with vehicle (Ctrl), hIAPP (10 μM) or control rat IAPP (rIAPP, 10
μM). (f) IL-β ELISA of supernatants from LPS-primed BMDM pre-treated with Congo Red
(200 μM, 1 h) and incubated for 6 h with vehicle (Ctrl) or hIAPP (10 μM). Data in a, d-f are
mean ± s.d. of triplicate samples within a single experiment and are representative of three
independent experiments. Images in b-c are representative of three independent experiments.
Scale bar = 10 μm. *P<0.05.
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